ALK and non-small cell lung carcinoma: Moreover, in the previously treated advanced non-small-cell lung cancer (NSCLC) with ALK rearrangement, targeted therapy with ALK inhibitors such as crizotinib has shown superiority compared to standard chemotherapy [26].